Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Clinical Trial to Evaluate the Safety and Immunogenicity of a 24-valent Pneumococcal Polysaccharide Conjugate Vaccine in People Aged 18 Years and Older

NCT06678620 is registered in ClinicalTrials.gov with Reinovax Biologics Co., LTD as lead sponsor.

NCT NCT06678620
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06678620 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Clinical Trial to Evaluate the Safety and Immunogenicity of a 24-valent Pneumococcal Polysaccharide Conjugate Vaccine in People Aged 18 Years and Older
Lead sponsor
Reinovax Biologics Co., LTD
Phase
Phase 2
Overall status
Completed
Start date
April 20, 2024
Completion date
December 12, 2024
Enrollment
992 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

pneumococcal infectious disease